TY - JOUR
T1 - Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain
T2 - Win, Miranda prediction of Chagas cardiomyopathy
AU - Win, Sithu
AU - Miranda-Schaeubinger, Monica
AU - Gustavo Durán Saucedo, Ronald
AU - Carballo Jimenez, Paula
AU - Flores, Jorge
AU - Mercado-Saavedra, Brandon
AU - Camila Telleria, Lola
AU - Raafs, Anne
AU - Verastegui, Manuela
AU - Bern, Caryn
AU - Tinajeros, Freddy
AU - Heymans, Stephane
AU - Marcus, Rachel
AU - Gilman, Robert H
AU - Mukherjee, Monica
AU - Chagas Working Group
N1 - © 2022 Published by Elsevier B.V.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Chagas disease is an endemic protozoan disease with high prevalence in Latin America. Of those infected, 20-30% will develop chronic Chagas cardiomyopathy (CCC) however, prediction using existing clinical criteria remains poor. In this study, we investigated the utility of left ventricular (LV) echocardiographic speckle-tracking global longitudinal strain (GLS) for early detection of CCC.Methods and results: 139 asymptomatic T. cruzi seropositive subjects with normal heart size and normal LV ejection fraction (EF) (stage A or B) were enrolled in this prospective observational study and underwent paired echocardiograms at baseline and 1-year follow-up. Progressors were participants classified as stage C or D at follow-up due to development of symptoms of heart failure, cardiomegaly, or decrease in LVEF. LV GLS was calculated as the average peak systolic strain of 16 LV segments. Measurements were compared between participants who progressed and did not progress by two-sample t-test, and the odds of progression assessed by multivariable logistic regression. Of the 139 participants, 69.8% were female, mean age 55.8 ± 12.5 years, with 12 (8.6%) progressing to Stage C or D at follow-up. Progressors tended to be older, male, with wider QRS duration. LV GLS was -19.0% in progressors vs. -22.4% in non-progressors at baseline, with 71% higher odds of progression per +1% of GLS (adjusted OR 1.71, 95% CI 1.20-2.44, p = 0.003).Conclusion: Baseline LV GLS in participants with CCC stage A or B was predictive of progression within 1-year and may guide timing of clinical follow-up and promote early detection or treatment.
AB - Background: Chagas disease is an endemic protozoan disease with high prevalence in Latin America. Of those infected, 20-30% will develop chronic Chagas cardiomyopathy (CCC) however, prediction using existing clinical criteria remains poor. In this study, we investigated the utility of left ventricular (LV) echocardiographic speckle-tracking global longitudinal strain (GLS) for early detection of CCC.Methods and results: 139 asymptomatic T. cruzi seropositive subjects with normal heart size and normal LV ejection fraction (EF) (stage A or B) were enrolled in this prospective observational study and underwent paired echocardiograms at baseline and 1-year follow-up. Progressors were participants classified as stage C or D at follow-up due to development of symptoms of heart failure, cardiomegaly, or decrease in LVEF. LV GLS was calculated as the average peak systolic strain of 16 LV segments. Measurements were compared between participants who progressed and did not progress by two-sample t-test, and the odds of progression assessed by multivariable logistic regression. Of the 139 participants, 69.8% were female, mean age 55.8 ± 12.5 years, with 12 (8.6%) progressing to Stage C or D at follow-up. Progressors tended to be older, male, with wider QRS duration. LV GLS was -19.0% in progressors vs. -22.4% in non-progressors at baseline, with 71% higher odds of progression per +1% of GLS (adjusted OR 1.71, 95% CI 1.20-2.44, p = 0.003).Conclusion: Baseline LV GLS in participants with CCC stage A or B was predictive of progression within 1-year and may guide timing of clinical follow-up and promote early detection or treatment.
KW - Chagas disease
KW - Chagas cardiomyopathy
KW - Echocardiography
KW - Strain imaging
KW - EUROPEAN-ASSOCIATION
KW - AMERICAN-SOCIETY
KW - ECHOCARDIOGRAPHY
KW - RECOMMENDATIONS
KW - BENZNIDAZOLE
U2 - 10.1016/j.ijcha.2022.101060
DO - 10.1016/j.ijcha.2022.101060
M3 - Article
C2 - 35647262
SN - 2352-9067
VL - 41
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
M1 - 101060
ER -